Half-facepiece reusable elastomeric respirators are an effective and viable option for protecting health care workers from exposure to airborne transmissible contaminants or infectious agents — for example, influenza virus — during day-to-day work or with a sudden or rapid influx of patients, such as during a public health emergency, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Today the National Academies of Sciences, Engineering, and Medicine released its review of the National Toxicology Program’s (NTP) draft monograph Systematic Review of Fluoride Exposure and Neurodevelopmental and Cognitive Health Effects.

The entrance to the planned 17,000 sq.-foot Korean American National Museum to be built in Koreatown. ; Credit: Morphosis Architects

The Korean American National Museum is on pace to break ground next year on the corner of Vermont and Sixth.

New designs unveiled this week show an airy, modern-looking building that will include elements of Korean design and house photographs and other artifacts.  

Read more on LAist.com.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Coronavirus deaths in the U.K. have passed those in Italy. Workers in the intensive care unit at the Royal Papworth Hospital in Cambridge are shown gearing up to care for COVID-19 patients.; Credit: Neil Hall/AP

Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths.

The country has surpassed Italy in COVID-19 deaths. The U.S. still leads the world in the highest number of coronavirus deaths; over 70,270 had died from the disease as of Tuesday.

The number of total deaths recorded in the U.K. is "higher than we would wish, I think is all I can say," Angela McLean, chief scientific adviser of Ministry of Defence said during the country's press briefing Tuesday.

McLean also emphasized that deaths in U.K. care homes have been steadily rising and said the trend was something the country "need[s] to get to grips with."

"I don't think we'll get a real verdict on how well countries have done until the pandemic is over," British Foreign Secretary Dominic Raab said Tuesday. "And particularly until we have comprehensive international data on all causes of mortality."

Since different countries collect and report coronavirus data using different methods, the comparisons between regions are not perfect. As more time passes and more tests are conducted and more data comes in, coronavirus death rates will become more precise.

The peak in deaths comes as other European countries, including Italy and Spain, are easing shelter-in-place restrictions, while U.K. Prime Minister Boris Johnson is expected to modify Britain's orders in the next week.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

A recent study compared the decentralised treatment of pharmaceutical contaminants in wastewater at hospitals with centralised treatment at conventional and upgraded wastewater plants. The results suggest that additional (post) treatments may not always provide significant benefits.

Tourism businesses operating in protected conservation areas in Europe engage in a high number of sustainable practices, a recent survey of over 900 small-to-medium enterprises (SMEs) reveals. Reasons for their sustainable behaviour include cutting costs, improving company image and lifestyle choices.

The global production, trade and use of goods and services has a significant impact on the environment — and rates of consumption are rising. A new study combines two assessment methods to quantify the impact of European trade on the environment. It finds that, overall, the EU was a net importer of environmental impact from 2000 to 2010, that machinery, equipment and vehicles contributed most to the EU’s export impacts and that the EU’s trade balance (import impact minus export impact) is increasing over time. The two assessment methods complement one another well and could form the basis for future country or region-wide studies, suggest the researchers, by enabling a detailed analysis of individual steps within a product’s trade flow, while also providing a larger picture of the overall process.

Increasing resource efficiency is a central aim of European environmental policy, and effective waste management must play a key role in this. A new report assesses waste management in 32 European countries, and identifies key lessons. Landfill taxes and mandatory separate collections of different waste types are highlighted as particularly successful policy instruments.

The EU Joint Research Centre has produced a new part of the handbook that provides guidelines for developing and using Life Cycle Assessments (LCA), which evaluate the environmental impacts of products, focusing specifically on life cycle impact assessment (LCIA). It recommends that assessments should be comprehensive, accessible and easy to apply in order to make LCA a more mainstream concept in decision-making.

Higher public awareness of sustainable fishing practices, led by environmental NGOs, may have helped reduce the incidence of mislabelled fish in the UK, compared to Ireland, according to a recent study which assessed levels of fish fraudulently sold as ‘cod’ in these two countries.

Since the arrival of the European Soil Data Centre in 2006, assessing the state of soils at European level has never been easier, more efficient or more reliable, according to a new report by its designers. The database, which contains state-of-the-art scientific information for a range of key environmental concerns, was accessed 26,000 times in the first 11 months of operation.

Standardised methods of categorising environmental data are needed at European and international levels for effective international policies. A recent study has concluded that a European framework that harmonises environmental data at the continental scale corresponds well with national classification systems, although some modifications may be needed to capture small-scale regional variations.

The impact of air quality on public welfare is important to policy development. However, it is difficult to make a clear link between the two when air pollution tends to be reported at a country level and wellbeing is an individual measure. A new study takes a step further towards linking the two by analysing regional level air quality across the EU and relating it to levels of life satisfaction.

A Bosnian pine (Pinus heldreichii) growing in the highlands of northern Greece has been dendrocronologically dated to be more than 1075 years old. This makes it currently the oldest known living tree in Europe. The millenium old pine was discovered by scientists from Stockholm University (Sweden), the University of Mainz (Germany) and the University of Arizona (USA).

read more

A new Pan-European landscape map (LANMAP) has been developed that allows a common classification of landscapes across Europe.

The development of Green Infrastructure (GI) in a UK case study has been researched in a recent study. Some issues caused by an imbalance in stakeholder power and conflicting roles played by major stakeholders were identified with the project. Stakeholder participation is central to the concept of GI and the research reiterates the importance for those implementing GI to ensure that participation is effective and balanced.

Over 8% of land in Europe could be at moderate-to-high risk of wind-driven soil erosion, a new study has estimated. In the first assessment of its kind, the researchers produced maps which show wind erosion risk across 36 countries. This information could help guide actions to tackle land degradation.

An analysis of flash flood forecasting in Europe has produced recommendations for emergency planners and others to improve flood risk management in vulnerable regions. In particular, the researchers recommend improved data collection and sharing, a common European policy for flash flood forecasting, and that local risk management recognises the specific challenges presented by flash floods.

Researchers have created a simple tool to analyse the risk of river flooding across almost all of Europe, and to estimate the associated economic losses. They found that Eastern Europe, Scandinavia, Austria and the UK are the regions and countries most at threat.

Cultural and institutional barriers, coupled with a lack of confidence about whether and how to use it, mean that the European Flood Awareness System (EFAS) has yet to be fully integrated into national flood warning systems, according to a recent study.

The reduction in summer storms in the western Mediterranean could be partly caused by land use change on coasts and mountain slopes, a new study reports. This lack of storms causes water vapour to build up above the region and may lead to heavy rainfall and flooding in central Europe.

Extreme and catastrophic floods in Europe, such as those seen in 2013, currently occur approximately once every 16 years, but this may increase to once every 10 years by 2050, according to new research. The study also suggests that annual average economic losses caused by extreme floods could reach almost five times higher than 2013 values.

Agriculture plays a large role in the management of water in the EU. However, there is little consistent information on water use in irrigation. New EU supported research has estimated how much water is used for irrigation in European countries, providing a framework to analyse agricultural pressures on water quantity.

A new combination of three models has explored the future dynamics of European livestock distribution. The results indicate that, without environmental policy, livestock density will increase both inside and outside current livestock hotspots. This will also occur to a certain degree with regulation, but the risk of negative impacts will be less likely.

A new study has described how agricultural management of the British potato crop has changed over time to reduce several serious threats to food security. It is crucial that an EU plant health policy framework continues to build on these successes to protect against new diseases emerging from expanding global trade and a changing climate.

A new study suggests that abandoned farmland is widespread in Europe and that not all land that has been abandoned is unsuitable for farming. Understanding how abandoned farmland is distributed may be important for making land management decisions – for instance, recultivation versus reversion to forest.

Soil erosion is an important issue in Europe, with consequences for water quality, ecosystem services supply and crop production. In this study, researchers enhanced an existing model to estimate soil loss and create an updated map of soil erosion across the EU. The authors say the tool can simulate the effects of land use changes and management practices and will support effective policy decisions.

The Global Allergy and Asthma European Network (GA2LEN), established in 2005 to facilitate excellence in allergy research across clinical and research institutions in Europe, has recently published a report on its major achievements.

Pollen allergy is a common cause of allergic respiratory diseases such as hay fever and asthma. A recent continent-wide study suggests that rising carbon dioxide (CO2) emissions over the last 30 years may be increasing pollen counts especially in European cities, which could have serious consequences for public health.

The impact of air quality on public welfare is important to policy development. However, it is difficult to make a clear link between the two when air pollution tends to be reported at a country level and wellbeing is an individual measure. A new study takes a step further towards linking the two by analysing regional level air quality across the EU and relating it to levels of life satisfaction.

Forests can play a critical role in the mitigation of climate change, but at the same time, climate change is threatening the health and condition of forests. Therefore their protection and adaptation is essential. The EU has adopted a green paper on 'Forest protection and information in the EU: preparing forests for climate change'. This special thematic issue provides current information on the dynamics and relationships between forests and climate change and insight into the role of forest management and ecosystem services in protecting EU forests.

To meet demand, more and more water is being abstracted from the land and transported long distances. This thematic issue addresses the most pressing policy issues within this field as Europe looks for an effective strategy to deal with water supply and consumption.

Managing landscapes effectively requires the involvement of a wide variety of stakeholders. The views and interests of these different groups can be effectively integrated by agri-environment 'collaboratives' — a type of bridging organisation which can be found in varying forms in Europe. Using data from Germany and the Netherlands, a study concludes that these groups make important contributions to landscape management, ranging from implementing policy to generating income.

The noise generated by commercial shipping can impair the ability of the critically endangered European eel to avoid predators, new research has found. The results show that marine noise can have serious effects on these animals with potentially fatal consequences.

A recent survey of businesses in France, Germany and the UK has revealed that they recycle and refurbish much of their waste electrical and electronic equipment (WEEE). However, some of this information is not being reported under the EU’s WEEE Directive because the waste is being disposed of informally or by contractors, rather than by manufacturers who are responsible for the whole life cycle of the products.

Standards for environmental management, such as EMAS and ISO 14001, aim to help organisations become more sustainable, but they have received little evaluation. A new Italian study is the first to quantitatively compare the impacts of these two standards. Its results suggest that EMAS's stipulation that organisations must report their ongoing performance may bring sustained environmental benefits in the longer term.

The factors enabling eco-innovation have been analysed across 19 European countries in a new study. Regulations and environmental subsidies were found to be more important factors in Eastern Europe than in wealthier Western European countries. External research and development (R&D) was also more relevant in Eastern Europe, demonstrating the need for specific technology transfers from other countries and competitors.

A recent study has analysed risks to European renewable industries from the Chinese supply of critical raw materials. The offshore wind sector was found to be the most vulnerable of the renewable industries to supply risks. EU and industry strategies should be able to deal with these supply risks in the short term, but there are potential long-term risks to solar and wind sectors. The development of alternative technologies less reliant on these raw materials, and methods to recycle these materials is, therefore, a priority.

Heatwaves in Europe are likely to become more frequent and devastating, according to recent research. Climate change will lead to extended periods of high day and night-time temperatures, coupled with high humidity, and will particularly affect the Mediterranean coast and southern European river basins, where there are many densely populated urban areas.

A review of the European Climate Change Programme has concluded that the initiative has successfully identified cost-efficient policy measures to reduce greenhouse gas (GHG) emissions, allowed consensus-building among key stakeholders, and positioned the European Union as a leader in climate change actions.

The impact of climate change on electricity consumption is important to both adaptation and mitigation policies. New research has estimated that over the next 100 years climate change could cause up to a 20 per cent decrease in demand for electricity for heating in Northern Europe and up to a 20 per cent increase in demand for electricity for cooling in Southern Europe.

Scientists have calculated carbon budgets for croplands in Europe, based on field measurements from nine sites across Europe. They found that significant soil carbon losses occurred from cropping even though some farmers used measures to enhance carbon-sequestration. These results may challenge findings from some other modelling studies if they turn out to be typical for all EU croplands.

Connecting Europe and North Africa with a single, long-distance electricity ‘supergrid’ is technically possible and the cheapest option available to meet Europe’s renewable energy targets, according to new research. However, significant political challenges, such as minimising the perception of risk and attracting sufficient investment, need to be overcome.

A different picture of greenhouse gas (GHG) emissions can be achieved if responsibility for emissions from different economic sectors is placed with the end energy users, according to a new report from the European Environment Agency (EEA). This approach makes sectors such as households responsible for many emissions that would otherwise be attributed to the energy industry.